

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC AND
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC,
Patent Owner.

Case IPR2018-00608
Patent 9,161,926

**DECLARATION OF PROFESSOR ALEXANDER M. KLIBANOV
IN SUPPORT OF PATENT OWNER'S RESPONSE TO PETITION FOR
INTER PARTES REVIEW**

**AMN1075
Amneal v. Almirall, LLC
IPR2019-00207**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
A. Background and Qualifications	1
B. Materials Considered.....	4
II. SUMMARY OF OPINIONS.....	8
III. LEGAL STANDARDS	10
IV. THE '926 PATENT.....	11
V. PROSECUTION HISTORY OF THE '926 PATENT.....	14
VI. EFFECTIVE FILING DATE OF THE '926 PATENT.....	17
VII. PERSON OF ORDINARY SKILL IN THE ART	18
VIII. BACKGROUND RELATING TO THE INVENTION OF THE '926 PATENT	18
A. Dapsone	19
B. General Principles of Pharmaceutical Formulation	21
1. <i>Considerations for Topical Products</i>	22
C. Acne Treatments.....	27
D. Rosacea Treatments.....	29
E. Solvents	30
F. Polymeric Viscosity Builders	33
IX. PETITIONER'S PRIOR-ART REFERENCES	36
A. WO 2009/061298 ("Garrett") (Ex. 1004).....	37

B.	International Publ. No. WO 2010/072958 A2 (“Nadau-Fourcade”) (Ex. 1005).....	45
C.	Giulia Bonacucina <i>et al.</i> , “Characterization and stability of emulsion gels based on acrylamide/sodium acryloyldimethyl taurate copolymer.” <i>AAPS PharmSciTech</i> 10(2): 368–375 (2009) (“Bonacucina”) (Ex. 1015).....	49
D.	U.S. Patent Publ. No. 2006/0204526 (“Lathrop”) (Ex. 1007)	50
E.	U.S. Patent Publ. No. 2010/0029781 (“Morris”) (Ex. 1008).....	51
F.	David W. Osborne, “Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products.” <i>J. Cosmetic Dermatology</i> 10: 324–329 (2011) (“Osborne I”) (Ex. 1009).....	53
G.	Aczone [®] Gel 5% Package Insert (2005) (“2005 Aczone 5% PI”) (Ex. 1010)	55
H.	U.S. Patent No. 7,820,186 (“Orsoni”) (Ex. 1011).....	55
I.	Epiduo [®] Prescribing Information (2008) (“Epiduo PI”) (Ex. 1012)...	56
J.	U.S. Patent Publ. No. 2007/0190019 (“Guo”) (Ex. 1013).....	56
K.	U.S. Patent No. 5,863,560 (“Osborne II”) (Ex. 1016)	57
L.	Viscosity of Carbopol [®] Polymers in Aqueous Systems (2010) (“Lubrizon Technical Data Sheet”) (Ex. 1020).....	59
M.	“Formulating Semisolid Products” (2008) (“Lubrizon Pharmaceutical Bulletin 21”) (Ex. 1021)	59
N.	Diane M. Thiboutot <i>et al.</i> , “Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.” <i>Clin. Pharmacokinet.</i> 46: 697–712 (2007) (“Thiboutot”) (Ex. 1023)	59
O.	Sepineo [™] P 600 Brochure (Ex. 1026)	60
P.	Laurie Barclay, “Use of topical corticosteroids for dermatologic conditions reviewed.” <i>Medscape</i> (2009) (“Barclay”) (Ex. 1027).....	60

Q.	Jong-Yun Kim <i>et al.</i> , “Rheological properties and microstructures of Carbopol gel network system.” <i>Colloid Polym. Sci.</i> 281: 614–623 (2003) (“Kim”) (Ex. 1029).....	60
R.	Neutralizing Carbopol® and Pemulen® Polymers in Aqueous and Hydroalcoholic Systems (2002) (“Noveon Technical Data Sheet”) (Ex. 1030).....	60
S.	Suleyman Piskin <i>et al.</i> , “A review of the use of adapalene for the treatment of acne vulgaris.” <i>Therapeutics & Clinical Risk Management</i> 3(4): 621–624 (2007) (“Piskin”) (Ex. 1032).....	61
X.	THE CLAIMS OF THE ’926 PATENT WOULD NOT HAVE BEEN OBVIOUS.....	61
A.	The Combination of Garrett and Nadau-Fourcade Does Not Render the Claims of the ’926 Patent Obvious.....	62
1.	<i>A POSA Would Not Have Been Motivated to Select the Dapsone of the Claimed Invention or Its Claimed Concentration of About 7.5% w/w</i>	64
2.	<i>A POSA Would Not Have Increased the Concentration of DGME Above 25% w/w</i>	71
3.	<i>The Claimed Concentration Range of the Polymeric Viscosity Builder Comprising A/SA Copolymer Was Not Obvious</i>	79
B.	The Combination of Garrett and Bonacucina Does Not Render the Claims of the ’926 Patent Obvious.....	83
1.	<i>A POSA Would Not Have Been Motivated to Select the Dapsone of the Claimed Invention or Its Claimed Concentration of About 7.5% w/w</i>	83
2.	<i>A POSA Would Not Have Increased the Concentration of DGME Above 25%</i>	87
3.	<i>The Claimed Concentration Range of the Polymeric Viscosity Builder Comprising A/SA Copolymer Was Not Obvious</i>	91

C.	Objective Indicia Further Support the Non-Obviousness of the Claims of the '926 Patent.....	95
1.	<i>The Statements and Evidence in Dr. Kevin Warner's Declaration Show Unexpected Results of the Claimed Formulation</i>	96
XI.	CONCLUSION.....	103

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.